We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Based on the results of a phase 2 trial, UK-based Synairgen said Monday that its antiviral SNG001 reduced the risk of severe disease in hospitalized COVID-19 patients. Read More
Preliminary data from a German phase 1/2 trial showed that Pfizer’s and BioNTech’s mRNA-based coronavirus vaccine candidate is safe and generated immune responses in participants, the companies announced Monday. Read More
The British government announced Monday that it has reached COVID-19 vaccine supply deals with Pfizer/BioNTech and Valneva, locking in tens of millions of doses of their vaccine candidates for the country. Read More
In a first glimpse at the efficacy of a COVID-19 vaccine from AstraZeneca and the University of Oxford, highly anticipated clinical data found that it produces strong immune response. Read More
Once hailed by President Trump and others as a possible treatment for COVID-19, the antimalarial drug hydroxychloroquine continues to a thumbs down in a number of human studies, most recently for treatment of patients with mild infections and for hospitalized patients. Read More
Democrats on the House’s coronavirus crisis subcommittee have launched an investigation into federal contracts for producing drugs, drug ingredients and supplies essential in the pandemic that they claim have been awarded to businesses politically tied to the Trump administration “without competition or transparency.” Read More
Johnson & Johnson has announced that it will begin evaluating its experimental COVID-19 vaccine in its first clinical trial next week, beginning in Belgium on July 22 and the U.S. the following week. Read More
As research on COVID-19 vaccines advances at an unprecedented pace, Russian hackers have been attempting to steal research information, the UK’s National Cyber Security Centre (NCSC) reported Thursday. Read More